Breaking News
Get 50% Off 0
Nederlandse versie beschikbaar
Wilt u liever naar Investing.com's Nederlandse editie?
🧠 Smart money is quietly buying these undervalued gems
See Undervalued Stocks
Close

Intellia Therapeutics Inc (NTLA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Intellia Therapeutics Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.94 +0.16    +1.08%
15:59:59 - Closed. Currency in USD
After Hours
14.97
+0.03
+0.20%
22:55:15 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,708,785
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 14.46 - 15.28
Intellia Therapeutics Inc 14.94 +0.16 +1.08%

Intellia Therapeutics Inc Option Chain

 
View the NTLA options chain and compare options of Intellia Therapeutics Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell), along with their strike prices and expiration dates. Evaluate the prices and premiums associated with these options to make informed decisions about your trading strategies. Assess the Open Positions chart to find information about the distribution of open options contracts for NTLA stock at various strike prices and expiration dates. Gain insights into the options market sentiment and the potential trading activity surrounding the Intellia Therapeutics Inc stock.
Expiration Date:
Show:
Strike Price:
Apr 15, 2026 08:07PM GMT

Calls

Puts

Last Chg. Bid Ask Vol Strike Last Chg. Bid Ask Vol
12.5 0% 11.5 12.6 1 2.50 0.04 0% 0 0.05 1
9.2 0% 9.4 10 0 5.00 0 0% 0 0.05 0
8.5 -0.12% 8.2 9.2 2 6.00 0.05 0% 0 0.05 0
14.94
Price @ Apr 15, 2026 08:07PM GMT
0.25 -37.5% 0.2 0.35 292 15.00 0.5 0% 0.4 0.6 144
0.07 40% 0 0.1 136 16.00 2.05 0% 0.8 1.9 0
0.05 0% 0 0.05 7 17.50 3.6 0% 2 3.2 0

Open Positions

 Calls
 Puts
© 2016 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NTLA Comments

Write your thoughts about Intellia Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ciprian Gal
Ciprian Gal Dec 22, 2025 12:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
better opportunity than NTLA is RGNX
Ciprian Gal
Ciprian Gal Dec 08, 2025 8:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the FDA letter is coming out soon. 12$ by December 31
M H
M H Nov 15, 2025 2:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
be a contrarian
Panagiotis Sparis
Panagiotis Sparis Oct 30, 2025 4:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The company did a lousy job not explaining why this patient had these intense side effects. An investor with no medical or scientific knowledge who just follows the opinion of the masses and the trends will react due to fear of the unknown. I will buy again because I believe in the technology and the companies (let's not forget Regeneron's involvement)
Andre Silvestre
Andre Silvestre Oct 28, 2025 6:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It’s a long process to restart a clinical trial. It will take at least 2 months or more. In between the stock will reach 8 to 9 usd, and then jump again at the first good news.
ALPTEKIN DAG
JDAG Oct 27, 2025 6:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I will increase my position if it goes below $12. I don’t think the liver incident is directly caused by Intellia’s therapy
Giuseppe Giannachi
Giuseppe Giannachi Oct 27, 2025 1:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I believe 1 isolated case does not necessarily mean it is directly linked to the NTLA's therapy. I could however understand profit taking after months of rallying. Possibly, it this session could be considered as a huge dip in which to buy.
Teun de Vries
Teun de Vries Oct 27, 2025 1:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Agreed, watching the next few months closely. Could be a huge dip to buy.
Jose Mayo
Jose Mayo Oct 08, 2025 1:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
x25 (or more) in 2035 (or before)
Aditò Moro
Aditò Moro Sep 27, 2025 11:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The data readout in about 6 weeks looks very promising. HAE (Hereditary Angioedema): We’ll see long-term Phase 2 results with an open-label follow-up, plus redosing in the 25 mg cohort and placebo patients now receiving the actual drug — a strong opportunity to confirm durability and consistency of effect. ATTR-CM (Transthyretin Amyloid Cardiomyopathy): At least 2 years of follow-up data (with an additional year included) should provide a compelling view on sustained benefit and safety. Importantly, these updates are not just from Phase 3 or the large nex-z trial, but rather earlier studies that can already reinforce confidence in efficacy and support the growth story moving forward.
yoni דואר
yoni דואר Sep 25, 2025 8:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
look at symbol rxrx
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email